EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Extracellular vesicle surface display of αPD‐L1 and αCD3 antibodies via engineered late domain‐based scaffold to activate T‐cell anti‐tumor immunity

Rui Chen, Ziqin Kang, Wenhao Li, Tianshu Xu, Yongqiang Wang, Qiming Jiang, Yuepeng Wang, Zixian Huang, Xiaoding Xu, Zhiquan Huang iD

Journal of Extracellular Vesicles · 2024

DOI: 10.1002/jev2.12490 ↗

At a glance

Journal article in Journal of Extracellular Vesicles, 2024. Written by Rui Chen and 9 co-authors. Institution: Department of Oral and Maxillofacial Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P.R. China. Major MEDLINE topics: Extracellular Vesicles, B7-H1 Antigen, CD3 Complex, T-Lymphocytes. Cited 28 times so far (Crossref); 54 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Sun Yat-sen Pilot Scientific Research Fund, National Natural Science Foundation of China, Guangdong Provincial Medical Science and Technology Research.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Extracellular vesicles (EVs) are emerging as promising carriers for the delivery of therapeutic biologics. Genetic engineering represents a robust strategy for loading proteins of interest into EVs. Identification of EV‐enriched proteins facilitates protein cargo loading efficiency. Many EV‐enriched proteins are sorted into EVs via an endosomal sorting complex required for transport (ESCRT)‐dependent pathway. In parallel, viruses hijack this EV biosynthesis machinery via conserved late domain motifs to promote egress from host cells. Inspired by the similarity of biogenesis between EVs and viruses, we developed a synthetic, Late domain‐based EV scaffold protein that enables the display of a set of single chain variable fragments (scFvs) on the EV surface. We named this scaffold the Late domain‐based exosomal antibody surface display platform (LEAP). We applied the LEAP scaffold to reprogramme HEK293T cell‐derived EVs to elicit T‐cell anti‐tumor immunity by simultaneously displaying αPD‐L1 and αCD3 scFvs on the EV surface (denoted as αPD‐L1×αCD3 bispecific T‐cell engaging exosomes, BiTExos). We demonstrated that αPD‐L1×αCD3 BiTExos actively redirected T cells to bind to PD‐L1 + tumor cells, promoting T‐cell activation, proliferation and tumoricidal cytokine production. Furthermore, the αPD‐L1×αCD3 BiTExos promoted T‐cell infiltration into the tumor microenvironment to mitigate the tumor burden in vivo. Our study suggested that the LEAP scaffold may serve as a platform for EV surface display and could be applied for a broad range of EV‐based biomedical applications.

Subjects

MeSH terms (MEDLINE)

Extracellular VesiclesB7-H1 AntigenCD3 ComplexT-LymphocytesSingle-Chain AntibodiesHumansAnimalsHEK293 CellsMiceExosomesNeoplasmsLymphocyte Activation

Author keywords

EV engineeringbispecific T‐cell engagerimmunotherapylate domain

Substances

B7-H1 AntigenCD3 ComplexSingle-Chain AntibodiesCD274 protein, human

Authors and institutions

  • Department of Oral and Maxillofacial Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P.R. China.
  • Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P.R. China.
  • Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P.R. China.

ORCID profiles: Zhiquan Huang

Funding

  • Sun Yat-sen Pilot Scientific Research Fund
  • National Natural Science Foundation of China
  • Guangdong Provincial Medical Science and Technology Research
  • The Guangzhou Science and Technology Project
  • The Science and Technology Program of Guangdong
  • The Key Laboratory of Malignant Tumor Molecular Mechanism and Translational Medicine of Guangzhou Bureau of Science and Information Technology
  • The Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes, Sun-Yat-Sen University

Cite

APA

Chen, R., Kang, Z., Li, W., Xu, T., Wang, Y., Jiang, Q., Wang, Y., Huang, Z., Xu, X., & Huang, Z. (2024). Extracellular vesicle surface display of αPD‐L1 and αCD3 antibodies via engineered late domain‐based scaffold to activate T‐cell anti‐tumor immunity. Journal of Extracellular Vesicles. https://doi.org/10.1002/jev2.12490

Vancouver

Chen R, Kang Z, Li W, Xu T, Wang Y, Jiang Q, et al. Extracellular vesicle surface display of αPD‐L1 and αCD3 antibodies via engineered late domain‐based scaffold to activate T‐cell anti‐tumor immunity. Journal of Extracellular Vesicles. 2024. doi:10.1002/jev2.12490

BibTeX
@article{Chen2024,
  author = {Chen, Rui and Kang, Ziqin and Li, Wenhao and Xu, Tianshu and Wang, Yongqiang and Jiang, Qiming and Wang, Yuepeng and Huang, Zixian and Xu, Xiaoding and Huang, Zhiquan},
  title = {Extracellular vesicle surface display of αPD‐L1 and αCD3 antibodies via engineered late domain‐based scaffold to activate T‐cell anti‐tumor immunity},
  journal = {Journal of Extracellular Vesicles},
  year = {2024},
  doi = {10.1002/jev2.12490}
}
Start for free →